Find Clinical Trials

All CategoriesMedications / Interventions»Ii»Immunoglobulin G



Join Paid Clinical Trials



  • Conditions:   Advanced Melanoma;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: APX005M;   Drug: Cabiralizumab;   Drug: Nivolumab
    Sponsors:   Yale University;   Bristol-Myers Squibb;   Apexigen, Inc.
    Recruiting

  • Conditions:   Human Papillomavirus Infection;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chordoma;   Locally Advanced Chordoma;   Metastatic Chordoma;   Unresectable Chordoma
    Interventions:   Biological: Nivolumab;   Biological: Relatlimab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Breast Cancer;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Triple Negative Breast Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Cisplatin
    Sponsors:   University of Washington;   Merck Sharp & Dohme Corp.
    Not yet recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Mogamulizumab;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hodgkin's Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Umbralisib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Cutaneous Melanoma;   Mucosal Melanoma;   Ocular Melanoma;   Stage III Acral Lentiginous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIB Uveal Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IIIC Uveal Melanoma AJCC v7;   Stage IV Acral Lentiginous Melanoma AJCC v6 and v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Uveal Melanoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Relatlimab;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   IgG4-related Sclerosing Cholangitis;   IgG4-related Disease
    Intervention:  
    Sponsors:   Mayo Clinic;   Nagoya University
    Recruiting

  • Conditions:   Epithelial Neoplasms, Malignant;   Epithelial Tumors, Malignant;   Malignant Mesenchymal Tumor
    Intervention:   Drug: NHS-IL-12
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Triple -Negative Breast Cancer;   Estrogen Receptor Negative;   HER2/Neu Negative;   Anatomic Stage IV Breast Cancer AJCC;   Progesterone Receptor Negative
    Interventions:   Procedure: Biopsy;   Procedure: Chemokine Modulation Therapy;   Drug: Celecoxib;   Biological: Recombinant Interferon Alfa-2b;   Drug: Rintatolimod;   Biological: Pembrolizumab
    Sponsor:   Roswell Park Cancer Institute
    Recruiting

  • Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Prognostic Stage IV Breast Cancer AJCC v8;   Triple-Negative Breast Carcinoma
    Interventions:   Biological: Durvalumab;   Drug: Olaparib
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
    Interventions:   Biological: Fresolimumab;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   Maximilian Diehn;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non Small Cell Lung Cancer
    Intervention:   Drug: durvalumab
    Sponsor:   Liza Villaruz, MD
    Recruiting

  • Conditions:   Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papillomavirus-16 Positive;   Human Papillomavirus-18 Positive;   Metastatic Malignant Neoplasm;   Recurrent Anal Canal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Penile Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Refractory Malignant Neoplasm;   Stage IV Anal Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8
    Interventions:   Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Maternal Syphilis During Pregnancy - Baby Not Yet Delivered;   Congenital Syphilis
    Intervention:   Diagnostic Test: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
    Sponsors:   Stanford University;   Santa Clara Valley Medical Center
    Not yet recruiting

  • Conditions:   Head and Neck Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma
    Interventions:   Drug: Metformin;   Biological: Durvalumab
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Hydronephrosis;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant;   Renal Pelvis Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage II Renal Pelvis Cancer AJCC v7;   Stage II Ureter Cancer AJCC v7;   Stage II Urethral Cancer AJCC v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Biological: Durvalumab;   Procedure: Therapeutic Conventional Surgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ovarian Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Biological: Tremelimumab
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HNSCC;   Lip SCC;   Oral Cavity Cancer;   Oropharynx Cancer;   Larynx Cancer;   Hypopharynx Cancer;   Nasopharynx Cancer;   Sinonasal Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Head and Neck Neoplasms;   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
    Intervention:   Drug: Pembrolizumab, Cetuximab
    Sponsors:   Assuntina G. Sacco;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Folliculotropic Mycosis Fungoides;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Sezary Syndrome;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: External Beam Radiation Therapy;   Biological: Tremelimumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer;   Stage IVA Lung Cancer;   Stage IVB Lung Cancer
    Interventions:   Biological: Durvalumab;   Drug: Selumetinib;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy;   Biological: Tremelimumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Gliomas
    Intervention:   Drug: Nivolumab
    Sponsors:   Columbia University;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Oncology;   Solid Tumor;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Melanoma;   Bladder Cancer
    Interventions:   Drug: MRx0518;   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
    Sponsors:   4D pharma plc;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer
    Interventions:   Drug: AB154;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Conditions:   Malignant Neoplasms of Digestive Organs;   Colorectal Cancer
    Interventions:   Drug: Irinotecan;   Drug: PF-05082566;   Drug: Cetuximab
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Human Papillomavirus Positive;   Oropharyngeal Squamous Cell Carcinoma;   p16 Positive Neoplastic Cells Present;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Biological: Durvalumab;   Procedure: Modified Radical Neck Dissection;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Transoral Robotic Surgery;   Biological: Tremelimumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Ficlatuzumab
    Sponsors:   Dana-Farber Cancer Institute;   AVEO Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Stage IV
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: Stereotactic Body Radiotherapy
    Sponsors:   University of Wisconsin, Madison;   AstraZeneca;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cervical Adenosarcoma;   Cervical Adenosquamous Carcinoma;   Cervical Carcinosarcoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Mucinous Adenocarcinoma;   Endometrial Squamous Cell Carcinoma;   Endometrial Transitional Cell Carcinoma;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Epithelial Tumor;   Malignant Peritoneal Neoplasm;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Skin Melanoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma;   Uterine Corpus Carcinosarcoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Advanced CEACAM6-expressing Solid Tumors
    Interventions:   Drug: BAY1834942;   Drug: BAY1834942 + Pembrolizumab
    Sponsor:   Bayer
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Triple-Negative Breast Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Drug: RSLV-132;   Drug: Placebo
    Sponsor:   Resolve Therapeutics
    Recruiting

  • Conditions:   Metastatic Non-small Cell Lung Cancer;   Metastatic Triple-negative Breast Cancer
    Interventions:   Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: Pembrolizumab
    Sponsors:   Jenny C. Chang, MD;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory or Recurrent Hypermutated Malignancies;   Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
    Intervention:   Drug: Nivolumab
    Sponsor:   The Hospital for Sick Children
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Castleman Disease;   Digestive System Carcinoma;   Erdheim-Chester Disease;   Lip and Oral Cavity Carcinoma;   Lymphangioleiomyomatosis;   Malignant Endocrine Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Male Reproductive System Neoplasm;   Malignant Neoplasm;   Malignant Respiratory Tract Neoplasm;   Malignant Thoracic Neoplasm;   Malignant Urinary System Neoplasm;   Mesothelial Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma;   Neurofibromatosis Type 2;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Breast Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Digestive System Carcinoma;   Recurrent Female Reproductive System Carcinoma;   Recurrent Male Reproductive System Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Pharyngeal Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Malignant Neoplasm;   Soft Tissue Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage III Pharyngeal Cancer;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Pharyngeal Cancer;   Stage IVA Pharyngeal Cancer;   Stage IVB Pharyngeal Cancer;   Stage IVC Pharyngeal Cancer;   Thyroid Gland Neoplasm
    Interventions:   Biological: Bevacizumab;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Drug: Valproic Acid
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clinical Stage 0 Cutaneous Melanoma AJCC v8;   Clinical Stage I Cutaneous Melanoma AJCC v8;   Clinical Stage IA Cutaneous Melanoma AJCC v8;   Clinical Stage IB Cutaneous Melanoma AJCC v8;   Clinical Stage II Cutaneous Melanoma AJCC v8;   Clinical Stage IIA Cutaneous Melanoma AJCC v8;   Clinical Stage IIB Cutaneous Melanoma AJCC v8;   Clinical Stage IIC Cutaneous Melanoma AJCC v8;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Colitis;   Diarrhea;   Malignant Genitourinary System Neoplasm;   Pathologic Stage 0 Cutaneous Melanoma AJCC v8;   Pathologic Stage I Cutaneous Melanoma AJCC v8;   Pathologic Stage IA Cutaneous Melanoma AJCC v8;   Pathologic Stage IB Cutaneous Melanoma AJCC v8;   Pathologic Stage II Cutaneous Melanoma AJCC v8;   Pathologic Stage IIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIC Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Other: Best Practice;   Other: Biospecimen Collection;   Procedure: Endoscopic Procedure;   Procedure: Fecal Microbiota Transplantation;   Biological: Infliximab;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Vedolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Prostate Cancer;   Prostate Disease
    Interventions:   Drug: Nivolumab;   Radiation: Brachytherapy;   Radiation: External Beam Radiation Therapy;   Drug: Androgen Deprivation Therapy
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Anetumab Ravtansine;   Biological: Bevacizumab;   Drug: Paclitaxel
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diabetes Complications;   Diabetes Mellitus;   Diabetic Neuropathies
    Interventions:   Drug: IGIV-C;   Drug: 0.9% Sodium Chloride
    Sponsors:   Beth Israel Deaconess Medical Center;   Grifols Biologicals, LLC
    Recruiting

  • Conditions:   Sickle Cell Disease;   Pain
    Interventions:   Drug: Immune Globulin Intravenous;   Other: Normal saline
    Sponsor:   Albert Einstein College of Medicine
    Recruiting

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   GlaxoSmithKline
    Recruiting

  • Conditions:   Lung Non-Small Cell Carcinoma;   PD-L1 Overexpression;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Solid Tumors;   Mycosis Fungoides;   Melanoma;   Merkel-cell Carcinoma;   Squamous Cell Carcinoma;   Breast Carcinoma;   Human Papillomavirus-Related Malignant Neoplasm;   Soft Tissue Sarcoma
    Interventions:   Drug: TTI-621 Monotherapy;   Drug: TTI-621 + PD-1/PD-L1 Inhibitor;   Drug: TTI-621 + pegylated interferon-α2a;   Other: TTI-621 + T-Vec;   Other: TTI-621 + radiation
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Biological: DS-8273a;   Biological: Nivolumab
    Sponsors:   New York University School of Medicine;   Bristol-Myers Squibb;   Daiichi Sankyo, Inc.
    Recruiting

  • Conditions:   Lymphoma;   Myeloma
    Interventions:   Drug: TTI-622 Monotherapy;   Drug: TTI-622 + Rituximab;   Drug: TTI-622 + PD-1/PD-L1 Inhibitor;   Drug: TTI-622 + Proteasome-inhibitor Regimen
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Condition:   Advanced Solid Tumors
    Interventions:   Drug: Avelumab;   Drug: NHS-IL12;   Drug: Avelumab (Once weekly);   Drug: NHS-IL12 (MTD);   Drug: Avelumab (Expansion cohort)
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Conditions:   Hematologic Malignancies;   Solid Tumor
    Interventions:   Drug: TTI-621;   Drug: TTI-621 plus Rituximab;   Drug: TTI-621 plus Nivolumab
    Sponsor:   Trillium Therapeutics Inc.
    Recruiting

  • Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: AB928;   Drug: AB122
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Condition:   Atopic Dermatitis
    Interventions:   Drug: Tralokinumab;   Drug: Placebos
    Sponsor:   LEO Pharma
    Recruiting

  • Condition:   Advanced Solid Malignancies
    Interventions:   Biological: MEDI4736 (Durvalumab);   Biological: MEDI4736 (Durvalumab) + Tremelimumab
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Eosinophilic Gastritis;   Eosinophilic Gastroenteritis
    Interventions:   Drug: AK002;   Other: Placebo
    Sponsor:   Allakos, Inc.
    Recruiting

  • Condition:   Non-small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Durvalumab
    Sponsor:   AstraZeneca
    Not yet recruiting

  • Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Psoriasis
    Interventions:   Drug: M1095;   Drug: Placebo;   Drug: Secukinumab
    Sponsors:   Bond Avillion 2 Development LP;   Avillion LLP
    Recruiting

  • Conditions:   EGFR Activating Mutation;   EGFR NP_005219.2:p.T790M;   Lung Carcinoma Metastatic in the Brain;   Lung Non-Small Cell Carcinoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anaplastic (Malignant) Meningioma;   Atypical Meningioma;   Grade II Meningioma;   Grade III Meningioma;   Recurrent Meningioma;   Supratentorial Meningioma
    Interventions:   Biological: Bevacizumab;   Procedure: Electric Field Therapy;   Device: NovoTTF-200A Device;   Procedure: Quality-of-Life Assessment
    Sponsors:   Northwestern University;   NovoCure Ltd.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Biological: Durvalumab;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Pemetrexed Disodium;   Radiation: Photon Beam Radiation Therapy;   Radiation: Proton Beam Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting

  • Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Post-polio Syndrome
    Interventions:   Biological: Flebogamma 5% DIF;   Other: Placebo
    Sponsors:   Grifols Therapeutics LLC;   Instituto Grifols, S.A.
    Recruiting

  • Conditions:   Neuromyelitis Optica;   Devic's Disease;   NMO Spectrum Disorder
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer Metastatic;   Non Small Cell Lung Cancer;   Nonsquamous Nonsmall Cell Neoplasm of Lung
    Interventions:   Drug: AB928;   Drug: AB122;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Pembrolizumab
    Sponsor:   Arcus Biosciences, Inc.
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Drug: GSK3359609;   Drug: Tremelimumab;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Cetuximab
    Sponsors:   GlaxoSmithKline;   MedImmune LLC
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Atezolizumab;   Drug: Hu5F9-G4
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting

  • Condition:   Stiff-Person Syndrome
    Interventions:   Drug: Intravenous Immunoglobulins, Human;   Drug: Placebos
    Sponsors:   Mayo Clinic;   Grifols Biologicals, LLC
    Recruiting

  • Conditions:   Solid Tumor;   Ovarian Cancer
    Interventions:   Drug: Hu5F9-G4;   Drug: Avelumab
    Sponsors:   Forty Seven, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting

Login to Get Started